Cell and Gene-Based Approaches to Heart Failure
This article was originally published in Start Up
Executive Summary
In heart failure, neither drugs nor devices can address a cascade of interrelated biomolecular and hemodynamic processes. These ultimately result in increased heart muscle fatigue, adverse ventricular remodeling, continuing loss of left ventricular ejection fraction, and all the other conditions that have created, in 2006, a heart failure product industry with $2.8 billion in product revenues, according to Current and Emerging Technologies for the Management of Heart Failure in the US, a report recently published by Medtech Insight. Looking to the future, there are currently a number of academic research institutions and biotechnology companies focused on the prophylaxis, containment, and potential reversal of the progression of heart failure with cellular transplants and gene therapy designed to accomplish myocardial tissue repair.
You may also be interested in...
Cardiac Cell Therapy: Are There Easier Ways to Restore Function? Probably
Discussions at the Transcatheter Cardiovascular Therapeutics meeting reinforced the notion that too little is known about cardiac cell therapy to usefully proceed with large-scale studies. Some suggested it'd be more useful to focus on small-molecule or device-oriented approaches to restoring contractile function.
In Cardiac Regeneration, it's Repair, not Replace
Recent clinical trial failures in cardiac stem cell therapies have been widely reported as raising more questions than answers in a field which already had many unknowns. But those questions themselves give rise to new strategies spurring the formation of start-ups like those profiled in this issue. While the new companies are ultimately addressing heart failure, they hope to intervene much earlier in the cascade of damage and remodeling, where turning up the body's natural healing responses a notch could help it repair the damage caused by myocardial infarction or ischemia. Many cardiac cell and gene therapy companies are returning to ischemic disease, a field in which, in recent years, the success of device-based revascularization techniques appeared to present a competitive hurdle to cell and gene therapies. Microvessel disease is emerging as a large market in which cell and gene therapies might have advantages over devices.
Medtronic: Making Convergence Pay
Medtronic has been a pioneer in drug/device convergence: creating products whose therapeutic benefit stems equally from the features of their drug and device components. Convergence represents one of the medical device industry's most promising opportunities. But getting past the cultural differences between medical device and biotech companies can be huge.